Economic evaluation of high-dose (80mg/day) atorvastatin treatment compared with standard-dose (20mg/day to 40mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

The Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial demonstrated incremental cardiovascular benefit of treatment with high-dose atorvastatin (80mg/ day) versus standard-dose simvastatin (20mg/day to 40mg/day) in 8888 patients with a previous myocardial infarction (MI) over a median follow-up period of 4.8 years.